Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26).
Fiche publication
Date publication
novembre 2021
Journal
International journal of radiation oncology, biology, physics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr DROUILLARD Antoine, Pr NOEL Georges, Pr PEIFFERT Didier, Dr ROUFFIAC-THOUANT Magali, Dr BOUSTANI Jihane
Tous les auteurs :
Crehange G, M'vondo C, Bertaut A, Pereira R, Rio E, Peiffert D, Gnep K, Benezery K, Ronchin P, Noel G, Mineur L, Drouillard A, Blanc J, Rouffiac M, Boustani J
Lien Pubmed
Résumé
Increasing dose of chemoradiotherapy in locally advanced esophageal cancer unsuitable for surgery has been a matter of debate in the last 2 decades. Advances in tumor staging and radiation targeting with modern imaging and IMRT should allow further testing exclusive radiation dose escalation in esophageal cancer.
Référence
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S5